MedKoo News:

May 7, 2024- Product VU534 Patent licensing News

MedKoo is excited to announce the licensing of patents of the novel compound VU534 from Vanderbilt University. VU534, a breakthrough compound, is now featured on our website at https://medkoo.com/products/55763. VU534 is a NAPE-PLD activator with an EC50 of 0.30 μM. Several lines of evidence suggest that reduced NAPE-PLD activity could contribute to cardiometabolic diseases. VU534 was shown to increase efferocytosis by bone-marrow derived macrophages isolated from wild-type mice, while efferocytosis was significantly reduced in Napepld-/- BMDM or after Nape-pld inhibition. . This groundbreaking product is safeguarded by patents including World Patent WO 2023/201014 A1

 

May 7, 2024- Product ML-327 Patent licensing News

MedKoo is excited to announce the licensing of patents of the novel compound ML-327 from Vanderbilt University. ML-327, a breakthrough compound, is now featured on our website at https://www.medkoo.com/products/23549. ML327 is a blocker of MYC. ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand. ML327 blocks MYC expression and tumor formation in neuroblastoma. This groundbreaking product is safeguarded by patents including US Patent US 9,783,510

 

 

May 7, 2024- VU0453595 Patent licensing News

MedKoo is excited to announce the licensing of patents of the novel compound VU0453595 from Vanderbilt University. VU0453595, a breakthrough compound, is now featured on our website at https://www.medkoo.com/products/14489.  VU0453595 is a novel M1 positive allosteric modulator (PAM), potential in schizophrenia.. This groundbreaking product is safeguarded by patents including US Patent US 10,654,847

 

May 7, 2024- V-9302 Patent licensing News

MedKoo is excited to announce the licensing of patents of the novel compound V-9302 from Vanderbilt University. V-9302, a breakthrough compound, is now featured on our website at https://www.medkoo.com/products/28980 .  V-9302 is a competitive antagonist of transmembrane glutamine flux (ASCT2 inhibitor), selectively and potently targeting the amino acid transporter ASCT2. This groundbreaking product is safeguarded by patents including US Patent US 10,793,514.

 

May 7, 2024- VU6028418 Patent licensing News

MedKoo is excited to announce the licensing of patents of the novel compound VU6028418 from Vanderbilt University. VU6028418, a breakthrough compound, is now featured on our website at https://www.medkoo.com/products/48056. VU6028418 is a Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor (mAChR) Antagonist. VU6028418 was subsequently evaluated as a preclinical candidate for the treatment of dystonia and other movement disorders. This groundbreaking product is safeguarded by patents including World Patent WO 2021119265 A1.

 

March 22, 2024- AUTAC4 Patent licensing News

MedKoo is excited to announce the licensing of patents pertaining to the novel compound AUTAC4 from Tohoku University, Japan. AUTAC4, a breakthrough compound, is now featured on our website at https://www.medkoo.com/products/49782. AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC4 downregulates cytosolic proteins and promotes targeted mitochondrial turnover via mitophagy. This groundbreaking product is safeguarded by patents including JP Patent No.: 7370579, US Patent No.: 11512084, and EP Publication No.: 3679935.

 

January 17, 2024 - MedKoo Relocates Headquarters to a New, Expanded Facility

 MedKoo, a leading supplier of biochemical reagents and small molecule drugs for research purposes, is pleased to announce its relocation to a new, expanded headquarters. The company's new address is: 2224 Sedwick Road Suite 102, Durham, NC 27713, USA. The move to this new facility marks an important milestone for MedKoo as it continues to grow and expand its operations. The new location offers increased space and improved facilities, allowing MedKoo to better serve its customers and meet the growing demand for its products. "We are excited to announce the relocation of our headquarters to this new, expanded facility," said Dr. Qingqi Chen, CEO of MedKoo. "This move represents a significant step forward for our company and will enable us to continue providing high-quality products and exceptional service to our customers." Customers and partners are encouraged to update their records with MedKoo's new address. All other contact information, including phone numbers and email addresses, will remain unchanged. For more information about MedKoo and its products, please visit www.medkoo.com 

 

September 22, 2022-MedKoo Awarded Biomedical Research Contract by the National Institutes of Health (NIH)

MedKoo, a leading supplier of biochemical reagents and small molecule drugs for research purposes, is proud to announce that it has been awarded a biomedical research contract by the National Institutes of Health (NIH). Under Contract Number 75N95022P00731, MedKoo will contribute to cutting-edge biomedical research initiatives supported by the NIH. "We are honored to have been awarded this contract by the National Institutes of Health," said Dr. Qingqi Chen, CEO of MedKoo. "This opportunity is a testament to the quality and reliability of our products and services, and we are excited to contribute to important biomedical research efforts." As part of this contract, MedKoo will provide high-quality biochemical reagents and small molecule drugs to support NIH-funded research projects. For more information about MedKoo and its products, please visit www.medkoo.com.

 

September 09, 2021-MedKoo Awarded Biomedical Research Contract by the National Institutes of Health (NIH)

 MedKoo, a leading supplier of biochemical reagents and small molecule drugs for research purposes, is delighted to announce that it has been awarded a research contract by the National Institutes of Health (NIH). Under Contract Number 75N95021P00528, MedKoo will contribute to cutting-edge research initiatives supported by the NIH. "We are thrilled to have been awarded this research contract by the National Institutes of Health," said Dr. Qingqi Chen, CEO of MedKoo. "This opportunity underscores the quality and reliability of our products and services, and we are excited to support important research efforts." As part of this contract, MedKoo will provide high-quality biochemical reagents and small molecule drugs to support NIH-funded research projects. For more information about MedKoo and its products, please visit www.medkoo.com.